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The urokinase plasminogen activator (uPA) and its receptor 
(uPAR) play important roles in physiological processes such as 
wound healing, infl  ammation, and stem cell mobilization, as well 
as in severe pathological conditions such as HIV-1 infection, 
tumor invasion, and metastasis (Alfano et al., 2002; Sidenius and 
Blasi, 2003; Gyetko et al., 2004; Selleri et al., 2005; Lund et al., 
2006). Besides uPAR’s well-established role in the regulation of 
pericellular proteolysis, it also modulates cell adhesion, migra-
tion, and proliferation through interactions with proteins pre-
sent in the extracellular matrix, including vitronectin (Vn) (Wei 
et al., 1994; Kjøller and Hall, 2001; Blasi and Carmeliet, 2002). 
The absence of transmembrane and intracellular domains ren-
ders uPAR signaling incompetent, and it is generally believed 
that signal transduction originating from this receptor must 
  involve lateral interactions with transmembrane proteins. In 
  accordance, uPAR-mediated processes have been proposed to 
require its interaction with membrane proteins including mem-
bers of the integrin family (Wei et al., 1996), chemokine recep-
tors (Resnati et al., 2002), and receptor tyrosine kinases (Liu 
et al., 2002).
The important role of uPAR in tumor cell adhesion, 
migration, invasion, and proliferation makes this receptor an 
attractive drug target in cancer treatment; however, this is com-
plicated by the extent of the published uPAR “interactome”. 
With such a goal in mind, the most important question becomes 
which of the many molecular interactions are really essential to 
mediate uPAR function. Recently, the crystal structures of uPAR 
in complex with a peptide antagonist (Llinas et al., 2005) and 
with the N-terminal fragment of uPA (Barinka et al., 2006; Huai 
et al., 2006) were presented, providing the fi  rst rational basis 
toward understanding how uPAR may organize its multiple 
molecular interactions. Attempts to identify the regions in uPAR 
involved in the specifi  c interaction with Vn and integrins have 
been published (Li et al., 2003; Degryse et al., 2005; Chaurasia 
et al., 2006; Wei et al., 2007); however, the results from these 
experiments are largely incongruent and remain to be confi  rmed 
in independent studies.
In this study we have applied a genetic approach, based on 
exhaustive mutagenesis and complementation experiments, to 
determine the essential direct molecular interactions required 
for uPAR to induce changes in cell morphology and migration. 
This was achieved in a comprehensive and unbiased way 
through a complete functional alanine scan of human uPAR in 
human embryo kidney (HEK) 293 cells. Of the 255 alanine sub-
stitutions analyzed, 34 were found to completely, or partially, 
impair uPAR-induced changes in cell morphology. The molecular 
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xpression of the membrane receptor uPAR induces 
profound changes in cell morphology and migra-
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we carried out a complete functional alanine scan of 
uPAR in HEK293 cells. Of the 255 mutant receptors char-
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and sufﬁ  cient to initiate downstream changes in cell mor-
phology, migration, and signal transduction. Collectively 
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cell adhesion molecule lacking inherent signaling capa-
bility evokes complex cellular responses by   modulating 
the contact between the cell and the matrix without the 
requirement for direct lateral protein–protein interactions.
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defect of all mutants was subsequently shown to be an im-
paired binding to the somatomedin-B (SMB) domain of Vn. 
Although the RGD motif in Vn was dispensable for uPAR-
dependent cell binding to Vn, it was implicated in subsequent 
signal transduction and changes in cell morphology, underscor-
ing the importance of integrin receptors downstream of uPAR 
in these processes. Although integrins are clearly involved in 
the cellular processes initiated by uPAR expression, we found 
strong evidence against any functional relevance of a direct 
molecular interaction between these molecules. First, all the 
mutants identifi  ed in the complete alanine scan have the same 
molecular defect (impaired Vn binding), suggesting that this 
is also the only required interaction. Second, alanine sub-
stitutions of the published integrin interaction sites in uPAR had 
no effect on receptor function. Finally, a recombinant GPI-
anchored plasminogen activator inhibitor-1 (PAI-1) molecule 
(PAI-1/GPI), which also binds Vn, mimicked the cellular effects 
of uPAR expression.
We conclude that a direct Vn interaction is both necessary 
and suffi  cient to initiate uPAR-induced changes in cell morphol-
ogy, migration, and signaling independently of direct lateral 
protein–protein interactions. The importance of the uPAR–Vn 
interaction was not cell type–specifi  c, as very similar data were 
obtained in CHO cells.
Results
Overexpression of uPAR in 293 cells 
induces signal transduction and changes 
in cell morphology and migration
It has been previously reported that expression of uPAR modu-
lates the adhesion and motility of 293 cells through interactions 
with Vn, integrins, and G protein–coupled receptors (Wei et al., 
1994, 1996, 1999, 2001; Degryse et al., 2005; Gargiulo et al., 
2005; Chaurasia et al., 2006;). In accordance, we fi  nd that ex-
pression of human uPAR in HEK293 Flp-In T-REx (293) cells 
induces changes in cell morphology, migration, and signaling 
(Fig. 1). The morphological changes include a general fl  atten-
ing of the cells, reduced cell–cell contact, disappearance of 
membrane ruffl  es, and formation of extensive lamellipodia (Fig. 
1 A, left panels), as well as a complete reorganization of the 
matrix-proximal F-actin cytoskeleton (Fig. 1 A, right panels). 
The changes in cell morphology refl  ect the cell motility induced 
by uPAR expression in these cells (Fig. 1 B and Video 1, available 
Figure 1.  Expression of uPAR in 293 cells induces changes 
in cell morphology, actin cytoskeleton, signal transduc-
tion, and cell migration. (A) uPAR-induced changes in cell 
morphology and F-actin cytoskeleton. 293 cells trans-
fected with a vector expressing human uPAR (293/uPAR) 
or empty vector (293/mock) were analyzed by phase-
contrast microscopy (left panels) and by TIR-FM after ﬁ  xa-
tion and staining with phalloidin-FITC (right panels). Bar, 
10 μm. (B) uPAR expression induces basal cell migration. 
Cell migration speed was quantiﬁ   ed using manual cell 
tracking of 293/mock and 293/uPAR cells monitored for 
30 min (1 frame every 15 s) by phase-contrast time-lapse 
recordings. The entire time-lapse movie, including overlay 
tracking, is Video 1 (available at http://www.jcb.org/
cgi/content/full/jcb.200612058/DC1). The number (n) 
of independent experiments in the dataset is indicated. 
The signiﬁ  cance levels are indicated and refer to com-
parisons with mock-transfected cells. (C) uPAR-induced 
ERK1/2 activation. Semi-conﬂ  uent 293/mock and 293/
uPAR cells were serum starved for 4 h before cell lysis and 
Western blotting analysis. Blots were ﬁ  rst probed for phos-
phorylated ERK1/2 (top blot) then stripped and reprobed 
for total ERK1/2 (bottom blot). The graph shows the mean ± 
SEM increase in the ratio between phosphorylated and 
total ERK/1/2 induced by uPAR expression. The number 
(n) of independent experiments in the dataset is indicated. 
The signiﬁ  cance levels are indicated and refer to compari-
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at http://www.jcb.org/cgi/content/full/jcb.200612058/DC1). 
Migratory (Nguyen et al., 1999) and proliferative (Aguirre 
Ghiso et al., 1999) signaling downstream of uPAR involves 
activation of the Ras/MAPK signaling pathway, and in accor-
dance we found that uPAR-expressing cells had approximately 
threefold increased ERK1/2 activation as compared with mock-
transfected cells (Fig. 1 C).
uPAR-induced changes in cell morphology 
occur through Vn and require integrin-
dependent RGD engagement
As previously described (Wei et al., 1994, 1996; Gargiulo et al., 
2005), expression of uPAR in 293 cells resulted in a strong in-
crease in cell adhesion to Vn, whereas adhesion to other ECM 
proteins including fi  bronectin, type-1 collagen, and laminin was 
unaffected (Fig. 2 A). The binding sites for uPAR and integrins on 
Vn are distinct, with uPAR recognizing the SMB domain (Deng 
et al., 1996a), and integrins the adjacent RGD motif. To address 
the relative importance of uPAR versus integrin binding to Vn, we 
performed adhesion assays using a recombinant N-terminal frag-
ment of Vn (Vn(1–66)) that includes both the SMB domain and 
the RGD motif. In addition, we monitored adhesion to two vari-
ants of this fragment where either most of the SMB domain had 
been removed (Vn(40–66), representing essentially RGD alone), 
or the RGD sequence had been mutated into RAD (Vn(1–66)
RAD) 
(Fig. 2 A). Adhesion of 293/uPAR cells was supported as long as 
the SMB domain was present and was not affected by mutating 
the RGD motif. Mock-transfected 293 cells adhered poorly to 
all of these substrates and not at all to Vn(1–66)
RAD (Fig. 2 A). 
Profi  ling of Vn receptor expression by the 293 cells and antibody 
inhibition experiments (Fig. S1, A and B; available at http://www
.jcb.org/cgi/content/full/jcb.200612058/DC1) indicated that the 
weak RGD-dependent adhesion of mock-transfected 293 cells to 
Vn was mediated by the αvβ5 integrin. Collectively, the adhe-
sion data demonstrate that uPAR promotes cell adhesion to Vn 
through a direct interaction with the SMB domain, and not by 
inducing integrin binding to the RGD motif.
Although the RGD motif in Vn is dispensable for adhe-
sion of 293/uPAR cells, it is at least partially required for the 
subsequent changes in cell morphology and signal transduction 
Figure 2.  uPAR induces RGD-independent cell adhesion to vitronectin and RGD-dependent changes in cell morphology and signal transduction. (A) uPAR 
promotes cell adhesion to the SMB domain of Vn. Schematic representation of the recombinant Vn fragments used in this study (left). Adhesion of uPAR and 
mock-transfected 293 cells were assayed by allowing cells to adhere for 30 min at 37°C to plates coated with the different substrates as indicated. The ad-
hesion is shown as the percentage of adhesion to poly-L-lysine–coated wells. Values represent the mean ± SEM of independent assays each done in qua-
druplicate. The number (n) of independent experiments is indicated. (B) RGD-dependent changes in cell morphology. Phase-contrast images of 293/mock 
and 293/uPAR cells seeded in serum-free medium on Vn(1–66) and Vn(1–66)
RAD for 2 h at 37°C. Bar, 10 μm. (C) RGD-dependent ERK1/2 activation. 
Serum-starved 293/uPAR cells were seeded on plates coated with Vn(1–66) or Vn(1–66)
RAD for 30 min. The medium was aspirated and the cell lysates 
prepared and analyzed by Western blotting for ERK1/2 activation as in Fig. 1. Graph indicates the mean ± SEM. The number (n) of independent experi-
ments in the dataset is indicated. The signiﬁ  cance levels are indicated and refer to comparisons with mock-transfected cells.JCB • VOLUME 177 • NUMBER 5 • 2007  930
(Fig. 2, B and C). Although 293/uPAR cells seeded on Vn(1–66) 
undergo marked changes in morphology, including cell fl  atten-
ing and extensive lamellipodia formation, these changes are ab-
sent when seeded on Vn(1–66)
RAD, where only a round adhesion 
patch can be observed under the cell body. Under the same con-
ditions, mock-transfected cells retain a rounded cell body, fail 
to form lamellipodia, and only extend thin membrane protru-
sions with limited matrix contact as evidenced also by the weak 
adhesive strength of these cells (Fig. 2 A). Mock-transfected 
cells remained completely round on Vn(1–66)
RAD in accordance 
with the adhesion data. When plated on Fn, no differences in 
cell adhesion and morphology were observed comparing 293/
mock and 293/uPAR cells (unpublished data). The level of 
ERK1/2 activation was higher (Fig. 2 C) when 293/uPAR cells 
were seeded on Vn(1–66) as compared with Vn(1–66)
RAD, sug-
gesting that also uPAR-induced downstream signaling is at least 
partially integrin dependent.
In summary, these data show that the ability of uPAR to 
induce changes in 293 cell morphology is a two-step process in 
which uPAR, through the direct interaction with the SMB do-
main of Vn, triggers cell attachment to the matrix. Subsequently, 
this initial adhesion is followed by engagement of integrins, 
possibly αvβ5, with matrix Vn, triggering changes in cell mor-
phology, migration, and signal transduction.
A direct Vn interaction is fundamental 
for the ability of uPAR to induce changes 
in cell morphology
In addition to the direct interaction with matrix Vn, extensive 
data suggests that the ability of uPAR to modulate cell adhe-
sion, migration, and proliferation requires a complex network 
of lateral interactions with a variety of membrane proteins in-
cluding integrins, receptor tyrosine kinases, and chemokine 
receptors. To address the nature of these lateral uPAR inter-
actions in a comprehensive and unbiased fashion, we next con-
ducted a complete functional alanine scan of uPAR in 293 cells. 
Receptor-induced changes in 293 Flp-In T-REx cells were 
chosen for this purpose for two reasons: (1) as shown in Fig. 1, 
uPAR expression in these cells causes very evident changes in 
cell morphology which can be scored easily by phase-contrast 
microscopy; and (2) in addition, the Flp-In system generates 
pools of isogenic transfectants carrying a single copy of the ex-
pression cassette, thus eliminating potential artifacts caused by 
clonal differences or heterogeneous expression levels.
We generated 255 single amino acid substitution mutants 
of uPAR by site-directed mutagenesis (all residues of mature 
uPAR excluding 28 cysteines) and expressed these in 293 Flp-In 
T-REx cells. As expected, the cell surface expression of all mu-
tant receptors was similar and comparable to that of wild-type 
uPAR as evaluated by FACS analysis and immunoblotting 
(Table I; Fig. S1, C and D; and Table S1 for a complete listing).
Of the 255 receptor variants analyzed, 34 were found to 
fully or partially impair the ability of uPAR to induce changes 
in cell morphology (listed in Table I). None of these residues 
coincided with previously identifi  ed interaction sites for Vn or 
integrins (Li et al., 2003; Degryse et al., 2005; Chaurasia et al., 
2006; Wei et al., 2007), but several are known to be involved in 
uPA binding (Gardsvoll et al., 2006). As the 293 cells do not 
  express uPA (Wei et al., 1994), the molecular defect of these 
mutants could not be explained by available evidence. Five of 
the mutants were found to suffer from severe folding problems 
as evidenced by the presence of high molecular weight covalent 
aggregates in immunoblotting experiments, and were not ana-
lyzed further (Table I and Fig. S1 D).
Because the initial step in uPAR-induced signaling and 
cell morphology changes is triggered by the direct binding to the 
SMB domain of Vn (Fig. 2), we next analyzed the adhesive 
properties of cells expressing the remaining 29 mutant receptors 
with impaired ability to change cell morphology (Fig. 3). Re-
markably, all of the mutant receptors displayed an impaired abil-
ity to promote cell binding to Vn(1–66)
RAD (Fig. 3 A). There was 
a strong correlation between the ability to induce changes in cell 
morphology and the reduction in uPAR binding to the SMB do-
main of Vn (Fig. 3 B), demonstrating a direct link between these 
parameters. Receptor mutants that did not impair the ability of 
uPAR to induce changes in cell morphology (S56A) as well as 
receptors containing mutations in published integrin interaction 
sites (E134A/E135A, S245A, H249A, and D262A) all displayed 
normal adhesion to the same substrate. All cell lines adhered 
equally well to Fn (Fig. S2 A, available at http://www.jcb.org/
cgi/content/full/jcb.200612058/DC1). Ligand binding has been 
demonstrated to enhance uPAR-dependent cell adhesion to Vn, 
and we therefore also performed the adhesion experiments in the 
presence of exogenously added pro-uPA (Fig. 3 C). Under these 
conditions the adhesion of most of the mutants was restored to 
that of wild-type uPAR, suggesting that ligand binding may 
compensate for the molecular defect of most of these mutants. 
The rescued Vn adhesion was also associated with restored 
uPAR cell morphology when cells were cultured in the presence 
of pro-uPA (Fig. S2 B). For some mutants (in particular W32A 
and R91A) cell adhesion and uPAR morphology was only par-
tially recovered by the addition of pro-uPA, suggesting that these 
may be key residues for the uPAR–Vn interaction.
Identiﬁ  cation of the Vn interaction site 
in uPAR
The location of the mutated residues on the published crystal 
structure of uPAR combined with the relatively small size of the 
SMB domain suggest that only part of the identifi  ed residues 
actually engage SMB directly. To identify this subset we next 
generated and expressed soluble variants of the mutant recep-
tors and assessed their binding to immobilized Vn (Sidenius 
et al., 2002). As we were seeking residues in the direct molecu-
lar interaction interface, the analysis was restricted to the 19 
mutant receptors where the substituted amino acid exhibits a 
surface exposure area on the published crystal structure above 
15Å
2. In these binding assays, five mutants (W32A, R58A, 
I63A, R91A, and Y92A) were found to display greater than 
fi  vefold reduction in binding to immobilized Vn (Fig. 3 D) 
while still having a normal binding to immobilized pro-uPA 
(unpublished data), suggesting that these residues are involved 
in the direct interaction with Vn. The impaired Vn binding of 
these mutants was observed also in the presence of excess pro-
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mutants is not related to impaired uPAR dimerization (unpub-
lished data).
On a molecular surface representation of the uPAR struc-
ture (Fig. 3 E), W32 and R91 defi  ne a composite epitope with 
residues located in both domain 1 and 2 of uPAR. The residues 
affected by the R58A, I63A, and Y92A substitutions are all lo-
cated close to these residues, suggesting that they may also en-
gage Vn directly. The Vn-binding epitope is located distal to the 
membrane anchorage position (indicated in cyan) and lies on 
the “top-back” of the molecule with respect to the central uPA-
binding cavity. Although we currently do not know the precise 
molecular explanation for the failure of the remaining mutant 
receptors to bind to Vn in the absence of pro-uPA, it should be 
stressed that from a functional point of view their defect is iden-
tical to that of W32A and R91A, i.e., impaired Vn binding.
The binding to matrix Vn is the only direct 
uPAR interaction required to trigger changes 
in cell morphology, migration, and signaling
The fact that all the mutants with impaired ability to induce 
changes in cell morphology share the same molecular defect in 
RGD-independent Vn binding suggests that this may also be the 
only important uPAR interaction required to trigger changes in 
cell morphology, migration, and signaling. This is particularly 
intriguing because the ability of uPAR to modulate cell adhe-
sion and migration has been shown previously to require direct 
uPAR–integrin interactions (Wei et al., 1996, 2007; Degryse et 
al., 2005; Gargiulo et al., 2005; Chaurasia et al., 2006). Individ-
ual (not depicted) or combined alanine substitutions (E134A/
E135A/S245A/H249A/D262A, termed uPAR/Int
−) in the pub-
lished integrin binding sites in uPAR had no effect on the ability 










L1A intermediate 116 ± 40 misfolded 45
T26A intermediate 168 ± 4 normal 2
L31A mock 81 ± 18 normal 32
W32A mock 97 ± 9 normal 69
E39A intermediate 95 ± 5 normal 99
K43A mock 89 ± 9 normal 24
N52A mock 112 ± 4 normal 71
R53A mock 122 ± 9 normal 46
T54A mock 118 ± 13 normal 19
L55A mock 158 ± 33 normal 38
Y57A mock 100 ± 4 normal 51
R58A mock 90 ± 6 normal 67
G60A mock 100 ± 4 normal 54
I63A mock 131 ± 14 normal 32
T64A intermediate 108 ± 8 normal 17
L66A intermediate 96 ± 7 normal 61
E68A intermediate 101 ± 9 normal 33
V70A mock 104 ± 34 normal 33
L75A intermediate 108 ± 5 normal 51
N77A mock 82 ± 38 misfolded 0
R91A mock 66 ± 12 normal
Y92A mock 61 ± 6 normal 99
L93A mock 121 ± 1 misfolded 39
S97A intermediate 86 ± 6 normal 0
L113A mock 98 ± 17 normal 14
E120A mock 134 ± 27 normal 12
L123A mock 112 ± 40 normal 5
R145A intermediate 159 ± 57 normal 0
G146A intermediate 80 ± 25 normal 0
F159A mock 277 ± 5 misfolded 1
F165A mock 182 ± 63 normal 0
F167A intermediate 103 ± 36 normal 14
N177A mock 145 ± 74 misfolded 4
G179A intermediate 101 ± 8 normal 31
aThe cell morphology of transfected 293 cells (morph.) is divided into three groups; wild-type uPAR morphology (uPAR), mock transfected morphology (mock), and 
intermediate morphology (intermediate).
bCell surface receptor expression was measured by FACS analysis. The mean ﬂ  uorescence (± SD) represents an average of three independent antibodies correlated 
to the expression level of wild-type uPAR.
cThe overall protein folding of the receptors was monitored by non-reducing SDS-PAGE and immunoblotting.
dSurface exposure area (Å
2) of the individual residues on the crystal structure of uPAR (PDB entry 1YWH) is indicated. No surface exposure is indicated for R91, 
as this residue is not deﬁ  ned in the crystal structure. A complete list of all mutants analyzed can be found in Table S1.JCB • VOLUME 177 • NUMBER 5 • 2007  932
of uPAR to induce changes in cell morphology and F-actin 
cytoskeleton (Fig. 4 A), Vn-adhesion   (Fig. 4 B), signaling (Fig. 
4 C), and cell migration (Fig. S3 A, available at http://www.jcb
.org/cgi/content/full/jcb.200612058/DC1). On the other hand, a 
single alanine substitution in the Vn-binding epitope (W32A) 
completely abolished all these cellular effects of uPAR expres-
sion. Although these data argue strongly against any functional 
relevance of direct integrin interaction(s) for the biological 
  activity of uPAR in our cell system, the single amino acid sub-
stitution strategy does not allow us to exclude the existence of 
additional and functionally redundant binding sites for integrins 
in uPAR.
To directly address the possibility that no lateral inter-
actions are required for the observed biological effects of uPAR 
expression, we conducted a genetic complementation experiment. 
PAI-1 shares no sequence or structural homology with uPAR; 
however, both molecules bind the SMB domain of Vn (Deng 
et al., 1996a). The Vn-binding site in PAI-1 is located distal from 
Figure 3.  The ability of uPAR to induce changes in cell morphology requires a direct Vn interaction. (A) Adhesion to Vn(1–66)
RAD of cells expressing uPAR 
single alanine substitution mutants, which completely (Mutant morph.) or partially (Intermediate morph.) fail to induce changes in 293 cell morphology. Four 
mutants that induced normal uPAR-like changes in cell morphology (uPAR morph.) were included in the analysis for comparison. The data are presented as 
the mean ± SEM of three independent experiments, each performed in quadruplicate as described in Fig. 1. (B) Correlation between cell morphology and 
cell adhesion to Vn(1–66)
RAD. Summary of the level of cell adhesion to Vn(1–66)
RAD as grouped by the mutants ability to induce morphology changes. The 
number (n) of uPAR mutants in each morphological group is indicated. Data are presented as means ± SEM. (C) Adhesion to Vn(1–66)
RAD as shown in 
panel A but with the adhesion conducted in the presence of 10 nM pro-uPA. (D) Identiﬁ  cation of the direct Vn-binding epitope using puriﬁ  ed proteins. Solu-
ble uPAR variants of the mutant receptors were tested for their ability to bind immobilized Vn. The mutants are arranged according to the position in the 
uPAR sequence. The data are presented as the mean ± SEM of three independent experiments each performed in triplicate. (E) Location of the Vn-binding 
site on the crystal structure of uPAR. A surface representation of the uPAR structure is shown in gray, and the positions of the alanine-substituted residues that 
cause a strong reduction in Vn binding using puriﬁ  ed proteins are   indicated in red. For comparison, a series of residues located in the uPAR ligand binding 
cavity and known to be involved in uPA binding are indicated in yellow. The most C-terminal residue (Q279) that is likely to be located close to the GPI 
anchor of membrane-tethered uPAR is indicated in cyan. The left panel is a “front” view of the uPA-binding cavity (Llinas et al., 2005) and the right panel 
is a “top” view (front view rotated 90° toward the observer). The images were constructed   using the coordinates deposited in the Protein Data Bank (PDB) 
with the code number 1YWH and the MacPyMOL software (http://pymol.sourceforge.net).DIRECT UPAR-INTERACTIONS IN CELL MIGRATION • MADSEN ET AL. 933
the C terminus to which we attached the GPI-anchoring signal of 
uPAR (Fig. S3 B). The resulting membrane-tethered PAI-1 
(termed PAI-1/GPI) was effi  ciently expressed on the cell surface 
(Fig. S3 C) and induced strong cell binding to Vn(1–66)
RAD (Fig. 
4 B). Remarkably, the expression of PAI-1/GPI in 293 cells in-
duced changes in cell morphology, adhesion, and ERK1/2 activa-
tion comparable to those induced by uPAR (Fig. 4, A–C). The 
ability of PAI-1/GPI to induce these changes in cell morphology 
strictly required its interaction with Vn, as the introduction of a 
triple alanine substitution that effi  ciently disrupts its interaction 
with Vn (R103A/M112A/Q125A, termed PAI-1/GPI/Vn
−) (Jensen 
et al., 2004) failed to induce any of these changes (Fig. 4, A–C).
Together these data demonstrate that a direct uPAR–Vn 
interaction is both required and suffi  cient to trigger changes in 
cell morphology, migration, and signal transduction. Other cru-
cial molecular events downstream of this interaction, including 
integrin engagement of the RGD motif in Vn, do not require any 
additional direct uPAR interactions.
A direct Vn interaction is required 
and sufﬁ  cient for uPAR to induce changes 
in cell morphology, adhesion, and signaling 
in CHO cells
The central importance of the Vn interaction in the biology of 
uPAR is not cell type specifi  c. When seeded at low density, 
CHO cells form colonies with an epithelial-like morphology 
characterized by tight cell–cell contact and a highly defi  ned 
colony contour (Fig. 5 A, left panels). In sharp contrast, CHO 
cells expressing high levels of uPAR form sparse colonies with 
no cell–cell contact. The expression of uPAR is also associated 
with marked changes in the organization of matrix-proximal 
F-actin cytoskeleton (Fig. 5 A, right panels). In analogy to the 
293 cell line, uPAR expression was associated with a strong 
and specifi  c increase in RGD-independent cell adhesion to Vn 
(Fig. 5 B) and caused increased ERK1/2 activation (Fig. 5 C).
Despite the obvious differences between the morphologi-
cal features of CHO and 293 cells, the direct Vn interaction was 
found to be required for the cellular effects of uPAR also in this 
cell line (Fig. 5). Alanine substitution in the Vn binding site 
(W32A) abolished the ability of uPAR to induce scattering of 
cells, changes in F-actin cytoskeleton, and ERK1/2 activation. 
As observed with the 293 cells, the exogenous addition of pro-
uPA rescued the uPAR cell morphology in a mutant-dependent 
manner (Fig. S4, available at http://www.jcb.org/cgi/content/
full/jcb.200612058/DC1). Furthermore, single alanine substitu-
tions (not depicted) or combinations of substitutions in the pub-
lished integrin interaction sites had no effect on uPAR function. 
Finally, the PAI-1/GPI receptor replicated uPAR-induced changes 
in a Vn-dependent manner also in this cell line.
A direct uPAR–Vn interaction is required 
for uPA-induced cell changes
All the mutants identifi  ed in this study fail completely or partially 
to induce cell adhesion to Vn in the absence of pro-uPA (Fig. 3 A), 
Figure 4.  A GPI-anchored PAI-1 chimeric molecule 
mimics uPAR function. (A) Analysis of cell morphology 
(left panels) and F-actin cytoskeleton (right panels) of 
293 cells expressing uPAR mutants with deﬁ  cient Vn 
binding (W32A), integrin interaction deﬁ  cient (Int
−) or 
the GPI-anchored PAI-1 molecule (PAI-1/GPI), and PAI-1/
GPI molecule deﬁ   cient in Vn binding (PAI-1/GPI/
Vn
−) were analyzed as described in Fig. 1. Bar, 10 μm. 
(B) Adhesive properties of 293 cells expressing uPAR/
W32A, uPAR/Int
−, PAI-1/GPI, and PAI-1/GPI/Vn
−. 
Data are presented as the mean ± SEM of three in-
dependent experiments performed in quadruplicate 
as described in Fig. 1. (C) ERK1/2-activation of 293 
cells expressing uPAR/W32A, uPAR/Int
−, PAI-1/GPI, 
and PAI-1/GPI/Vn
−. Serum-starved cells were ana-
lyzed for ERK1/2 activation as described in Fig. 1. A 
representative immunoblot is shown and the quantiﬁ  -
cation of (n) independent experiments is graphed as 
the mean ± SEM. Signiﬁ   cance levels are indicated 
and refer to comparisons with mock-transfected cells 
analyzed in parallel.JCB • VOLUME 177 • NUMBER 5 • 2007  934
yet their adhesive properties are in most cases restored to normal 
levels in the presence of exogenous pro-uPA (Fig. 3 C). As most 
of these mutants bind pro-uPA normally (unpublished data), they 
provide an important tool to dissect the importance of the direct 
Vn interaction in signal transduction induced by uPA binding as 
well as for the analysis of the cellular processes occurring subse-
quent to Vn engagement of the receptor. In the absence of exoge-
nous pro-uPA expression of W32A and T54A mutant receptors 
both fail to induce cell binding to Vn (Fig. 6 A) and both display 
a low level of ERK1/2 activation similar to that of mock-trans-
fected cells (Fig. 6 B). In the presence of the pro-uPA, cells ex-
pressing the T54A receptor, but not the W32A receptor, display a 
fully restored Vn binding (Fig. 6 A) and ERK1/2 activation state 
(Fig. 6 B). For comparison the Vn binding and ERK1/2 activa-
tion is constitutively high in cells expressing wild-type uPAR and 
only moderately affected by the addition of uPA. As the wild-
type, W32A and T54A receptors all bind pro-uPA equally well 
these data document that uPA signaling to ERK1/2 occurs through 
the induction of uPAR binding to Vn.
The recovery of Vn binding and ERK1/2 activation in-
duced by pro-uPA on cells expressing uPAR/T54A is paralleled 
by rapid changes in cell morphology and focal contact turn-
over as illustrated by the translocation of paxillin-GFP into 
newly formed lamellipodia (Fig. 6 C and Video 2, available 
at http://www.jcb.org/cgi/content/full/jcb.200612058/DC1) and 
by the scattering of preformed CHO colonies (Fig. 6 D and 
Video 3), which resembles a bona fi  de epithelial–mesenchymal 
transition. None of these uPA-induced changes were observed 
in cells expressing uPAR/W32A, underscoring the fundamental 
requirement for a direct uPAR–Vn interaction in these cellu-
lar processes.
Discussion
Using a systematic and unbiased approach, we demonstrate that 
a direct interaction between cell surface uPAR and the extra-
cellular protein Vn is required for the ability of uPAR to modulate 
changes in cell morphology, migration, and signal   transduction 
Figure 5.  A direct uPAR–Vn interaction is required and sufﬁ  -
cient to induce changes in cell morphology, actin cytoskeleton, 
and signaling of CHO cells. (A) Cell morphology (left panels) 
and F-actin cytoskeleton (right panels) of CHO cells trans-
fected with empty vector (mock), wild-type uPAR, the indicated 
uPAR mutants, and PAI-1/GPI constructs were analyzed as 
described in Fig. 1. Bar, 10 μm. (B) Adhesive properties of 
CHO cells transfected as in A. Data are shown as the mean ± 
SEM of three independent assays each done in quadrupli-
cate as described in Fig. 2. (C) ERK1/2 activation in CHO 
cells. Cells were serum starved overnight and analyzed for 
ERK1/2 activation as described in Fig. 1. The graph indi-
cates the mean ± SEM of (n) independent experiments. The 
signiﬁ   cance levels are indicated and refer to comparisons 
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in two different cell lines. This conclusion is based on two 
  central observations. All of the alanine substitutions that affect 
the ability of uPAR to induce changes in cell morphology and 
migration directly affect uPAR-mediated cell binding to Vn   
independently of integrin binding to the RGD motif of Vn. 
Furthermore, a GPI-anchored PAI-1 molecule, which shares only 
the binding site in the SMB domain of Vn with uPAR, induces 
cellular changes that are virtually identical to those induced 
by uPAR.
It has been extensively documented that the ability of 
uPAR to modulate cell adhesion, migration, and proliferation 
occurs through the regulation of integrin signaling (Wei et al., 
1996; Degryse et al., 2005; Gargiulo et al., 2005; Chaurasia 
et al., 2006). Our data are fully in accordance with this view as we 
observe that the RGD motif in Vn is involved in uPAR-mediated 
downstream signal transduction and changes in cell morphol-
ogy. Nevertheless, our data argue fi  rmly against a function-
ally relevant direct interaction between uPAR and integrins. 
Alanine substitutions in the previously published integrin inter-
action sites, alone or in combination, have no effect on uPAR 
function in both cell lines analyzed. We found no mutants with 
normal RGD-independent Vn binding and impaired ability to 
induce changes in cell morphology. Finally, an engineered PAI-1/
GPI molecule, which recapitulated the membrane–ECM inter-
action induced by uPAR, was suffi  cient to induce similar changes. 
Our data do not rule out direct uPAR–integrin interactions; how-
ever, they do allow us to conclude that if these interactions 
occur they are of little or no functional importance with respect 
to uPAR-induced changes in cell morphology, migration, and 
signaling, at least in 293 and CHO cells.
Based on binding assays using purifi  ed proteins and the 
presence of pro-uPA, we were able to identify fi  ve residues 
(W32, R58, I63, R91, and Y92) that, when mutated into alanine, 
impair the ability of uPAR to interact with Vn. Noticeably, when 
these fi  ve mutants were tested for their ability to mediate cell 
attachment to Vn in the presence of uPA, only two of them 
Figure 6.  A direct uPAR–Vn interaction is responsible for uPA-induced ERK1/2 activation, lamellipodia formation, and cell scattering. (A) Adhesion 
to Vn(1–66)
RAD of CHO cells transfected as indicated were assayed in the absence or presence of 10 nM pro-uPA. Data are shown as the mean ± 
SEM of three independent assays each done in quadruplicate. (B) ERK1/2-activation by uPA. CHO cells transfected as above were serum starved 
overnight and incubated for 10 min with 10 nM pro-uPA or left untreated. After cell lysis the levels of ERK1/2 activation was quantiﬁ  ed as described 
in Fig. 1. Data are shown as the mean ± SEM of (n) independent experiments. The signiﬁ  cance levels are indicated and refer to comparisons between 
with and without pro-uPA treatment. (C) Turnover of focal contacts induced by Vn engagement of uPAR. CHO cells expressing uPAR mutants W32A 
and T54A were transfected with a construct encoding GFP-tagged paxillin to label focal contact. Time-lapse recordings of paxillin distribution by 
TIR-FM were started immediately after the addition of 10 nM pro-uPA and continued for 15 min at 4 frames/min. The panel shows the ﬁ  rst (t = 0 min) 
and last (t = 15 min) frames of representative recordings. The entire movie is Video 2 (available at http://www.jcb.org/cgi/content/full/
jcb.200612058/DC1). (D) Epithelial–mesenchymal transition-like scattering of CHO cell colonies induced by Vn engagement of uPAR. CHO cells 
  expressing the W32A and T54A receptors were plated at low density and allowed to form colonies for 4 d. Phase-contrast time-lapse recordings 
were started immediately after addition of 10 nM pro-uPA and continued for 24 h (1 frame every 5 min). The panel shows the ﬁ  rst (t = 0 h) and the 
last (t = 24 h) frames of representative recordings. The entire time-lapse movie is Video 3 (available at http://www.jcb.org/cgi/content/full/jcb
.200612058/DC1). Bars, 10 μm.JCB • VOLUME 177 • NUMBER 5 • 2007  936
(W32 and R91) were still signifi  cantly impaired. These two res-
idues are therefore likely to represent the most important direct 
interaction site for Vn in uPAR. That we have identifi  ed the 
bona fi  de Vn-binding epitope in uPAR is supported by several 
structural, functional, and evolutionary observations: the bind-
ing epitope is located distal to the GPI anchor, as would be ex-
pected for a membrane receptor that interacts with a component 
of the ECM. The location of the binding site is different from 
the location of the uPA-binding site, allowing for the simultane-
ous binding of these two molecules. The composite epitope 
contains residues both in domain 1 (W32, R58, and I63) and 
domain 2 (R91 and Y92), explaining why proteolytic cleavage 
between these two domains abolishes binding (Høyer-Hansen 
et al., 1997; Sidenius and Blasi, 2000). All the residues in the 
identifi  ed epitope are exposed on the crystal structure of uPAR. 
Finally, all the residues are highly conserved between differ-
ent species.
How do we explain the mutants with impaired cell bind-
ing to Vn but normal binding when purifi  ed proteins are used? 
In contrast to cell binding assays, the binding of soluble uPAR 
to immobilized Vn cannot be measured in the absence of uPA 
(Sidenius et al., 2002). Several of the mutants (R53, L55, Y57, 
L113, E120, L123, R145, and G146) are located in the area 
of contact between domain 1 and 2 of uPAR, suggesting that 
the correct “docking” of these two domains is critical for Vn 
binding. Binding of uPA, which engages extensive areas of both 
  domain 1 and 2 of uPAR (Gardsvoll et al., 2006; Huai et al., 2006), 
may compensate for this defect by enforcing the correct Vn 
binding competent alignment of these two domains. In addition, 
the N52 and T54 mutants suggest that in the absence of uPA, 
glycosylation of uPAR at N52 is required for Vn binding. Par-
ticularly intriguing is the fi  nding that several of the mutant resi-
dues (L31, R53, L55, Y57, T64, L66, and E68) have their side 
chains exposed inside the uPA-binding cavity of uPAR. The fact 
that these residues were identifi  ed in a screen where uPA is ab-
sent suggests that something else, which is required for the abil-
ity of uPAR to bind Vn, is engaging this cavity in the absence of 
uPA and that this engagement is required for uPAR binding to 
Vn. The identity of this interaction has yet to be established, but 
based on the fi  nding that uPAR binding to Vn involves receptor 
dimerization (Sidenius et al., 2002; Cunningham et al., 2003), it 
is tempting to speculate that this interaction partner may be 
uPAR itself.
Interestingly, part of the Vn binding site identifi  ed in this 
study (R91 and Y92) maps to the previously identifi  ed chemo-
tactic epitope SRSRY located in the linker region connecting 
domain 1 and 2 of uPAR (Fazioli et al., 1997). However, it seems 
unlikely that this chemotactic activity is important in our cell 
systems, as most of the critical residues identifi  ed in this study 
do not map to this region, yet they do share the same molecu-
lar defect. Furthermore, PAI-1 does not contain an SRSRY se-
quence, yet does it mimic uPAR function. Interestingly, peptides 
covering this region (uPAR aa 84–95) have been shown to in-
hibit uPAR-dependent cell adhesion to Vn (Liang et al., 2003).
Although PAI-1/GPI closely mimic uPAR function with 
respect to the changes in cell adhesion, morphology, and signal 
transduction presented in this work, this molecule should be 
used as a uPAR mimic with caution, as it has cellular effects 
which are not seen with uPAR. These effects include a pro-
nounced tendency of the CHO cells to “lose pieces”, possibly 
because of an impaired lamellipodia retraction, as well as an 
impaired cytokinesis in the 293 cells (unpublished data). These 
effects are likely due to the fact that PAI-1 binds with much 
higher affi  nity to Vn than uPAR (Okumura et al., 2002).
In line with several other studies (Jo et al., 2003; Gargiulo 
et al., 2005; Chaurasia et al., 2006; Mazzieri et al., 2006), we 
observe that overexpression of uPAR leads to increased ERK1/2 
activation in both cell lines analyzed. A direct uPAR–Vn inter-
action is required for this activation, as Vn binding–defi  cient 
uPAR mutants display levels of active ERK1/2 comparable to 
those of mock-transfected cells. Interestingly, uPA binding to 
uPAR also leads to ERK1/2 activation in different experimen-
tal systems (Nguyen et al., 1998; Aguirre Ghiso et al., 1999), 
suggesting that both overexpression of the receptor and ligand 
binding induces the same signal transduction pathway(s), pos-
sibly through a common molecular mechanism. In line with 
other studies we have used systems with high-level expression 
of uPAR ( 3 × 10
6 binding sites per cell in both cell lines as 
determined by binding assays using Eu
3+-labeled pro-uPA; 
unpublished data), and under these conditions cell adhesion 
to Vn is independent of pro-uPA binding to uPAR (Wei et al., 
1994, 1996; Cunningham et al., 2003). At physiological ex-
pression levels, uPAR-dependent cell adhesion to Vn requires 
uPA binding (Waltz and Chapman, 1994; Sidenius and Blasi, 
2000; Sidenius et al., 2002). Consequently, it appears likely that 
uPA binding may actually induce “Vn signaling” by stimulat-
ing uPAR binding to matrix Vn. In support of this possibility 
we show that there is a strict correlation between the ability 
of pro-uPA to promote Vn binding and to induce ERK1/2-
activation and changes in cell morphology (Fig. 3, Fig. 6, Fig. 
S2 B, and Fig. S4).
What is the molecular mechanism of uPAR-induced “Vn 
signaling”? The TIR-FM images and adhesion assays clearly 
demonstrate that expression of uPAR dramatically increases the 
contact between the cell and the ECM. Although uPAR does so 
passively by a physical interaction with matrix Vn, it will invari-
ably bring all matrix receptors present in the plasma membrane 
in closer contact with their extracellular ligands. In the 293 cell 
line the uPAR-induced increase in cell/matrix contact triggers 
subsequent changes in cell morphology and signaling that are at 
least partially mediated by an RGD-dependent integrin, possi-
bly αvβ5. Although it is possible that uPAR and integrins bind 
contemporarily to the same Vn molecule, this does not seem to 
be required because PAI-1, which is known to block integrin 
binding to Vn (Stefansson and Lawrence, 1996), induces simi-
lar changes when tethered to the cell membrane.
Because the Vn-binding form of uPAR is associated with 
membrane structures known as lipid rafts (Cunningham et al., 
2003), the engagement of Vn by uPAR will bring these mem-
brane domains in contact with the matrix. Lipid rafts are en-
riched in signal transduction molecules (Simons and Toomre, 
2000) and the uPAR–Vn interaction will thus promote the tight 
encounter between the ECM, its different cell surface receptors, 
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different repertoires of membrane receptors and different matri-
ces have different repertoires of ligands, our data suggest that 
the single interaction between uPAR and Vn may be responsible 
for many of the proteolysis-independent biological effects initi-
ated by uPAR.
It is important to underscore that the conclusions of this 
work cannot be directly extrapolated to uPAR functions differ-
ent from its ability to induce changes in cell morphology, basal 
cell migration, and ERK1/2 activation. For example, we have 
not assayed the ability of the different uPAR mutants to modu-
late directional cell migration and cell proliferation. Conse-
quently, our data does not exclude nor confi  rm the requirement 
for additional direct uPAR interactions in these processes. 
Nevertheless, the identifi  cation of the Vn binding site presented 
here provides the fi  rst tool to directly address the importance of 
the Vn interaction in any experimental system where uPAR is 
expressed by transfection and/or infection. The single alanine 
substitution W32A effi  ciently disrupts the interaction with Vn 
while maintaining normal pro-uPA binding.
Materials and methods
Materials
CHO Flp-In and HEK293 Flp-In T-REx cells, expression vectors pcDNA5/
FRT/TO and pOG44, zeocin, blasticidin S HCl, and Ham’s F12 medium 
were from Invitrogen. Dulbecco’s modiﬁ  ed eagle medium (DME) and 
αMEM were from BioWhittaker. PBS, trypsin, glutamine, penicillin, and 
streptomycin were obtained from EuroClone, and fetal bovine serum (FBS) 
was from HyClone. Non-tissue culture plates were from Falcon Becton Dick-
inson. Tetracycline, poly-L-lysine, laminin (from Engelbreth-Holm-Swarm mu-
rine sarcoma), phalloidin-FITC, and CHO protein-free culture medium were 
from Sigma-Aldrich. FuGENE 6, ﬁ  bronectin, and Hygromycin B were from 
Roche. Type-1 collagen from rat tail was from BD Biosciences. Urea-puriﬁ  ed 
Vn was obtained from Promega. Pro-uPA was provided by Dr. Jack Henkin 
(Abbott Laboratories, Abbott Park, IL). Antibodies against total and 
phosphorylated ERK1/2 were from Cell Signaling Technology. Blocking 
antibodies against αvβ3 (LM609) and αvβ5 (P1F6) integrins were from 
Immunological Sciences. Monoclonal antibody against β1 integrin (mAb 13) 
was from BD Biosciences. Monoclonal antibodies against human 
uPAR and the PAI-1 polyclonal antibody were provided by Dr. Gunilla 
Høyer-Hansen (Finsen Laboratory, Copenhagen, Denmark) and Dr. Peter 
Andreasen (Århus University, Århus, Denmark), respectively. Goat anti–
mouse and goat anti–rabbit Ig F(ab′)2-FITC were from Jackson Immuno-
Research Laboratories.
Expression vector construction
The expression vector encoding full-length uPAR was generated by amplify-
ing (oligos uPARu and uPARd) the human uPAR cDNA (Roldan et al., 
1990) and cloned in the pcDNA5/FRT/TO vector using Kpn1/Not1. The 
expression vector encoding a GPI-anchored PAI-1 molecule was gener-
ated by uniting the complete PAI-1 coding region (aa −22 to 380), a 
short linker sequence (AlaGlyAlaGlyAlaGlyLys), and the GPI-anchoring 
signal sequence of uPAR (aa 276–313). The PAI-1 coding region and the 
linker region were generated by amplifying a HT1080 cDNA with oligos 
PAIu and PAId, and the GPI-anchor signal by amplifying the uPAR cDNA 
with oligos GPIu and uPARd. The PAI-1/linker fragment (Kpn1–HindIII) 
and the GPI fragment (HindIII–Not1) were assembled into Kpn1–Not1 
digested pcDNA5/FRT/TO. The Vn(1–66)/Fc fusion protein was gener-
ated by attaching the ﬁ  rst 66 amino acids of mature human Vn to a 
constant region of a human IgG. Primers and templates were as follows: 
a vector containing part of the Vn cDNA (pTrx-Vn(1–97) [Deng et al., 
1996b]) ampliﬁ  ed with oligonucleotides Vn(1–66)u and Vn(1–66)d and 
a vector containing an Fc region of human IgG (pIG-1 [Fawcett et al., 
1992]) ampliﬁ  ed with primers FcU and FcD. The Vn(1–66) (Kpn1–Xho1) 
and Fc (Xho1–Not) fragments were assembled in Kpn1–Not1 digested 
pcDNA5/FRT-TO. Variants of this construct where the SMB domain was 
deleted (Vn(40–66)/Fc) or where only the signal peptide was retained 
(Fc) were generated as above, substituting the oligo Vn(1–66)u with oligos 
Vn(40–66)u and SigU, respectively. The correct sequences of the complete 
coding regions of all constructs were veriﬁ  ed by sequencing. All oligo-
nuclotide sequences can be found in Table S1 (available at http://www
.jcb.org/cgi/content/full/jcb.200612058/DC1). The expression vector 
encoding paxillin-GFP was provided by Dr. Alan F. Horwitz (University of 
Virginia, Charlottesville, VA; Laukaitis et al., 2001).
Site-directed mutagenesis
Alanine substitutions were generated by site-directed mutagenesis accord-
ing to the QuikChange protocol (Stratagene). Alanine residues present in 
the uPAR sequence were substituted with glycine. Multiple rounds of muta-
genesis were used to generate constructs carrying multiple substitutions. 
Expression vectors encoding soluble uPAR variants were generated by a 
second round of site-directed mutagenesis changing codon 284 of uPAR 
into a stop-codon (oligo pair A284Stop).
Cell culture
Parental HEK293 Flp-In T-REx cells were cultured in DME supplemented 
with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin, 5 mM gluta-
mine, 15 μg/ml blasticidin, and 100 μg/ml zeocin at 37°C in 5% CO2. 
Parental CHO Flp-In cells were cultured in Ham’s F12 supplemented as 
above, but without blasticidin. Transfections were performed with a 1:10 
ratio of pcDNA5/FRT/TO-based expression vector and pOG44 using 
FuGENE 6, and stable HEK293 Flp-In T-Rex and CHO Flp-In transfectants 
were selected in medium lacking zeocin using 150 μg/ml and 300 μg/ml 
hygromycin B, respectively. Expression in HEK293 Flp-In T-REx was in-
duced by adding 1 μg/ml tetracycline to the medium overnight.
Expression and puriﬁ  cation of recombinant proteins
For the production of soluble uPAR mutants, semi-conﬂ  uent CHO Flp-In sta-
bly transfected with the relevant expression vectors was washed with PBS 
and incubated for 7–10 d in CHO protein-free medium. The concentration 
of suPAR in the conditioned media was typically higher than 100 nM as 
determined by ELISA. The conditioned medium was used for in vitro bind-
ing assays without further puriﬁ   cation. Recombinant Fc-fusion proteins 
were expressed in the same way, but were puriﬁ  ed by standard Protein A 
afﬁ  nity chromatography.
FACS analysis
Cell surface expression of integrins, uPAR, and PAI-1/GPI were analyzed 
by ﬂ  ow cytometry. αvβ3, αvβ5, and β1-integrins were detected using pri-
mary antibodies (10 μg/ml). PAI-1/GPI was detected using a polyclonal 
antibody (2 μg/ml) and uPAR was detected using the monoclonal anti-
bodies R2 and R4, as well as a polyclonal rabbit anti-uPAR antibody (all 
2 μg/ml). Cells were stained with appropriate secondary FITC-labeled 
  antibody (diluted 1:100) and analyzed by ﬂ  ow cytometry (FACSCalibur; 
BD Biosciences).
Scoring of cell morphology
For the scoring of cell morphology, changes induced by the different 
mutant receptors in semi-conﬂ  uent cells were inspected by phase-contrast 
microscopy by three to ﬁ  ve independent, trained observers. The observers 
were asked to score the morphology of the cells in comparison to uPAR and 
mock-transfected cells analyzed in parallel. A cumulative score of “uPAR” 
or “mock” morphology was assigned to clones where unanimous scoring 
by the individual observers was achieved. A cumulative score of “inter-
mediate” morphology was assigned to clones where the majority (two or 
more) of the observers gave an “intermediate” score.
Adhesion assays
Adhesion assays were performed as described previously (Cunningham 
et al., 2003). In brief, cells were harvested, counted, and allowed to adhere 
in the presence or absence of 10 nM pro-uPA for 30 min at 37°C to 96-well 
plates (3 × 10
4 cells/well) coated with the different substrates as indi-
cated. After washing, the adherent cells were ﬁ  xed, stained with crystal 
violet, and quantiﬁ  ed by measuring the absorbance at 540 nm. Coatings 
were as follows: 100 μg/ml poly-L-lysine, 10 μg/ml ﬁ  bronectin, 10 μg/ml 
type-1 collagen, 20 μg/ml laminin, and 1 μg/ml vitronectin (Vn). Vn(1–66), 
Vn(1–66)
RAD, Vn(40–66), and Fc were all coated at 1 μg/ml.
Total internal reﬂ  ection ﬂ  uorescence microscopy (TIR-FM)
Cells were plated on glass coverslips and allowed to adhere overnight in 
the presence (293 cells) or absence (CHO cells) of 1 μg/ml tetracycline. 
Cells were washed in PBS, ﬁ  xed in 4% paraformaldehyde, quenched with 
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and blocked with 2% BSA in PBS. Labeling of F-actin was performed using 
0.2 μg/ml phalloidin-FITC, 1% BSA in PBS. TIR-FM imaging of cells was 
performed using a Biosystem TIR-FM workstation (Olympus) based on the 
Cell^R Imaging System (Olympus). A 488-nm argon laser was coupled in 
an inverted epiﬂ  uorescence motorized microscope (IX81; Olympus) and 
focused at an off-axis position of the objective back focal plane. Cells 
plated on glass coverslips were viewed through a high-aperture 60× ob-
jective lens (UIS2 60× TIRFM PlanApo N, NA 1.45; Olympus) with an ad-
ditional 1.6× lens. Images (16-bit depth) were acquired using an Orca-ER 
(C4742-80) Cooled CCD digital camera (Hamamatsu). Coverslips were 
directly inserted into an Attoﬂ  uor Cell chamber (Invitrogen), rinsed with PBS 
(to maintain the requested difference of refractive indexes) and subjected 
to TIRF analysis. Time-lapse TIR-FM imaging was performed as above, with 
the exception that ﬁ  xation/permeabilization/staining was omitted and that 
the cells were maintained at 37°C in normal growth medium throughout the 
recordings (every 15 s for a total of 15 min). Adjustment of brightness/
contrast and smoothening of images was done using ImageJ 1.38i and 
always applied to the entire image.
Phase-contrast and time-lapse imaging
Phase-contrast and time-lapse live-cell imaging was performed at 37°C, 
5% CO2 with an inverted microscope (IX70; Olympus) equipped with an 
incubation chamber (Solent Scientiﬁ  c). Cells were always plated in serum-
containing growth medium unless otherwise stated, and viewed through 
20× (LCPlanFl, NA 0.4 Ph1, Olympus) or 40× (UIS2 40× UPlanFLN, NA 
0.75 Ph2; Olympus) objective lenses with an additional 1.5× lens. All 
time-lapse acquisitions were performed using the 20× objective. The ac-
quisition system includes a digital camera (Sensys; Roper Scientiﬁ  c) and 
System Control Software Metamorph 7.0r4 (Universal Imaging). Adjust-
ment of brightness/contrast and smoothening of images was done using 
ImageJ 1.38i and always applied to the entire image. Cell migration speed 
was quantiﬁ  ed with ImageJ 1.38i using the plug-in “manual tracking”. 
In each experiment, 20 randomly chosen cells were tracked and their aver-
age migration speed throughout the experiment was calculated.
Binding assays of puriﬁ  ed proteins
In vitro binding assays were performed essentially as described previously 
(Sidenius et al., 2002) using Nunc Maxisorb black-well plates for the de-
tection of bound suPAR with an Eu
3+-labeled polyclonal anti-uPAR antibody 
(0.5 μg/ml) followed by the measurement of time-resolved ﬂ  uorescence. 
Binding to immobilized Vn was measured using an excess of suPAR (80 nM) 
in the presence of a limiting concentration of pro-uPA (20 nM). All mea-
surements were done in triplicate, and the speciﬁ  c binding calculated by 
subtraction of the nonspeciﬁ  c binding to BSA-coated wells.
Cell lysis and Western blotting
Cells were washed and lysed directly on the culture dish in ice-cold lysis 
buffer (25 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, protease 
  inhibitor cocktail [Complete-EDTA-free], 1 mM PMSF, 1 mM EDTA, 1 mM 
NaF, and 1 mM Na3VO4). After clariﬁ  cation by centrifugation (16,000 rcf, 
15 min, 4°C) the total protein content was determined using the DC-Protein 
assay (Bio-Rad Laboratories) with BSA as standard. Equal amounts of total 
protein were separated by SDS-PAGE and probed as indicated.
Statistical analysis
The signiﬁ   cance of differences in cell adhesion and ERK1/2 activation 
states were established using t test (paired, two-tailed) after log-transformation 
of the data from independent experiments.
Miscellaneous
The surface-accessible area of the residues of uPAR was calculated based 
on the A-chain of pdb-entry 1YWH (Llinas et al., 2005). Calculations were 
performed using the program AREAIMOL from the CCP4 suite of programs 
(Collaborative Computational Project, Number 4, 1994) with a probe-
radius of 1.4 Å.
Online supplemental material
Fig. S1 (A and B) shows the profiling of Vn receptor expression and 
functionality in 293 cells. Fig. S1 (C and D) provides an example of com-
parable expression levels of the different mutants expressed in 293 cells. 
Fig. S2 A demonstrates that adhesion to Fn is unaffected by the expres-
sion of Vn-deficient uPAR mutants in 293 cells. Fig. S2 B and Fig. S4 
show the rescue of morphological changes induced by exogenous pro-
uPA for some uPAR mutants in 293 and CHO cells, respectively. Fig. 
S3 A indicates the migration speed of 293 cells expressing either Vn or 
integrin-deﬁ  cient uPAR mutants. Fig. S3 B illustrates the crystal structure of 
the PAI-1–SMB complex and the position of the attached GPI anchor. Fig. 
S3 C illustrates the comparable cell surface expression level of uPAR and 
PAI-1. Table S1 lists information on all the mutants generated in this study, 
as well as all sequences of all oligonucleotides used in the study. Video 1 
illustrates the increase in cell migration upon uPAR expression in 293 cells. 
Video 2 shows the redistribution of paxillin-GFP upon uPA-mediated res-
cue of uPAR/Vn binding in CHO cells. Video 3 shows the scattering ef-
fect upon uPA-mediated rescue of uPAR/Vn binding in preformed CHO 
colonies. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200612058/DC1.
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